David W Hoskin Selected Research

pleurocidin

1/2020	MDA-MB-231 Breast Cancer Cells Resistant to Pleurocidin-Family Lytic Peptides Are Chemosensitive and Exhibit Reduced Tumor-Forming Capacity.
12/2015	Enhanced killing of breast cancer cells by a d-amino acid analog of the winter flounder-derived pleurocidin NRC-03.
10/2013	Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts.
10/2011	Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David W Hoskin Research Topics

Disease

57	Neoplasms (Cancer) 02/2021 - 05/2002
23	Breast Neoplasms (Breast Cancer) 01/2020 - 03/2002
16	Carcinoma (Carcinomatosis) 01/2021 - 04/2005
12	Leukemia 12/2016 - 04/2005
8	Triple Negative Breast Neoplasms 01/2021 - 01/2014
5	Colonic Neoplasms (Colon Cancer) 10/2015 - 05/2002
4	Inflammation (Inflammations) 01/2022 - 04/2015
4	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2006
4	Ovarian Neoplasms (Ovarian Cancer) 10/2019 - 01/2010
4	Necrosis 08/2018 - 03/2002
3	Carcinogenesis 08/2020 - 09/2006
3	Multiple Sclerosis 01/2018 - 11/2012
3	Lymphoma (Lymphomas) 10/2013 - 03/2003
3	Mastocytoma 12/2005 - 05/2002
2	Multiple Myeloma 12/2015 - 10/2013
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2014 - 11/2012
2	Hematologic Neoplasms (Hematological Malignancy) 10/2013 - 05/2010
2	Intervertebral Disc Degeneration 09/2013 - 04/2012
1	Infections 01/2021
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 09/2020

Drug/Important Bio-Agent (IBA)

12	Peptides (Polypeptides)IBA 01/2022 - 04/2005
12	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 04/2005
10	Antimicrobial Cationic PeptidesIBA 02/2021 - 08/2006
9	lactoferricin BIBA 01/2022 - 04/2005
8	CaspasesIBA 01/2017 - 07/2003
7	PhytochemicalsIBA 01/2020 - 06/2008
7	Caspase 3 (Caspase-3)IBA 06/2010 - 07/2003
6	AlkaloidsIBA 01/2021 - 01/2013
6	piperineIBA 02/2020 - 01/2013
6	CytokinesIBA 01/2020 - 04/2012
6	Pharmaceutical PreparationsIBA 01/2019 - 04/2004
6	Adenosine (Adenocard)FDA LinkGeneric 03/2008 - 05/2002
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 06/2006
4	Propidium (Propidium Iodide)IBA 02/2020 - 10/2013
4	Annexin A5IBA 02/2020 - 04/2005
4	pleurocidinIBA 01/2020 - 10/2011
4	AntibodiesIBA 01/2020 - 05/2002
4	CurcuminIBA 11/2010 - 06/2008
4	CeramidesIBA 01/2010 - 05/2006
3	fluorescein carboxylateIBA 02/2020 - 10/2016
3	IronIBA 12/2019 - 10/2015
3	FlavonoidsIBA 09/2019 - 01/2015
3	Estrogen ReceptorsIBA 09/2019 - 01/2016
3	p38 Mitogen-Activated Protein KinasesIBA 08/2018 - 01/2007
3	LigandsIBA 10/2015 - 03/2002
3	Angiogenesis InhibitorsIBA 01/2014 - 11/2006
3	Cytotoxins (Cytolysins)IBA 01/2010 - 08/2006
3	Liposomes (Liposome)IBA 10/2009 - 06/2006
3	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 12/2007 - 09/2005
3	Okadaic AcidIBA 12/2007 - 09/2005
3	Paclitaxel (Taxol)FDA LinkGeneric 12/2005 - 03/2003
2	thiazolyl blueIBA 02/2020 - 01/2017
2	B7-H1 AntigenIBA 01/2020 - 10/2016
2	mastoparanIBA 01/2020 - 12/2016
2	3-hydroxypyridin-4-oneIBA 12/2019 - 10/2015
2	PolymersIBA 12/2019 - 10/2015
2	Chelating AgentsIBA 12/2019 - 10/2015
2	Fatty Acids (Saturated Fatty Acids)IBA 11/2019 - 10/2016
2	EstersIBA 11/2019 - 10/2016
2	Docosahexaenoic AcidsIBA 11/2019 - 10/2016
2	PolyphenolsIBA 11/2019 - 10/2016
2	PhlorhizinIBA 11/2019 - 10/2016
2	gingerolIBA 10/2019 - 01/2017
2	Cytostatic AgentsIBA 09/2019 - 02/2013
2	AntioxidantsIBA 01/2019 - 12/2007
2	Antimalarials (Antimalarial Agents)IBA 01/2019 - 01/2017
2	ArtesunateIBA 01/2019 - 01/2017
2	Cytochromes c (Cytochrome c)IBA 08/2018 - 04/2005
2	InterferonsIBA 09/2017 - 10/2016
2	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 02/2008
2	SuspensionsIBA 01/2017 - 01/2014
2	ApigeninIBA 10/2016 - 10/2014
2	Interleukin-6 (Interleukin 6)IBA 08/2016 - 01/2015
2	Biological ProductsIBA 01/2016 - 04/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 07/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015 - 11/2012
2	LipopolysaccharidesIBA 01/2015 - 09/2013
2	CollagenIBA 11/2014 - 01/2013
2	DNA (Deoxyribonucleic Acid)IBA 10/2014 - 07/2003
2	thymoquinoneIBA 01/2014 - 09/2012
2	Tamoxifen FDA LinkGeneric 03/2008 - 05/2006
2	ceramide glucosyltransferaseIBA 03/2008 - 05/2006
2	Purinergic P1 Receptors (Adenosine Receptor)IBA 03/2008 - 12/2005
2	Purine NucleosidesIBA 03/2008 - 05/2002
2	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 01/2007 - 09/2005
2	Caspase 9IBA 01/2007 - 04/2005
2	IntegrinsIBA 04/2004 - 05/2002
2	Fas Ligand Protein (Fas Ligand)IBA 07/2003 - 03/2002
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	HepcidinsIBA 02/2021
1	Antimicrobial PeptidesIBA 01/2021
1	Glutathione (Reduced Glutathione)IBA 01/2021
1	piperlongumineIBA 01/2021
1	Anthocyanins (Anthocyanin)IBA 09/2020
1	nitrosamine 4- (methylnitrosamino)- 1- (3- pyridyl)- 1- butanoneIBA 08/2020

Therapy/Procedure

9	Drug Therapy (Chemotherapy) 12/2019 - 03/2002
6	Therapeutics 01/2020 - 05/2006
5	Immunotherapy 01/2020 - 03/2002
1	Oral Administration 08/2020
1	Intraperitoneal Injections 08/2020